Cystic fibrosis–related diabetes (CFRD) is a distinct and common comorbidity that profoundly alters the trajectory of cystic fibrosis (CF). Unlike the more familiar type 1 or type 2 diabetes, CFRD arises from the unique pathophysiology of CF, combining a primary defect in insulin secretion with varying degrees of insulin resistance driven by chronic inflammation and infection. The clinical consequences of undiagnosed or poorly managed CFRD are severe: accelerated and irreversible decline in lung function, worsening nutritional failure, and a significantly elevated risk of mortality. Because CFRD typically develops insidiously over years, systematic screening is not merely a clinical recommendation but a cornerstone of comprehensive CF care that directly influences long-term survival. Without a rigorous screening protocol, the critical window for early intervention is frequently missed.

Epidemiology and Natural History

The prevalence of CFRD increases steadily with age. By age 10, roughly 5 to 10 percent of children with CF exhibit abnormal glucose tolerance. By age 20, the prevalence of CFRD reaches 20 to 30 percent, and by age 40, more than 50 percent of individuals with CF are affected. Women with CF are at particularly high risk and face a worse prognosis, partly due to the metabolic demands of pregnancy and sex-based differences in immune response. Those carrying severe CFTR mutations, such as F508del homozygotes, are also more likely to develop CFRD earlier. The presence of CFRD increases the risk of death by up to threefold compared to individuals with CF who have normal glucose tolerance. Importantly, a significant decline in forced expiratory volume in one second (FEV1) can occur in the year preceding a formal diagnosis of CFRD, underscoring the need for consistent, proactive detection rather than reliance on clinical symptoms.

Pathophysiology: Insulin Deficiency as the Core Defect

The development of CFRD begins with the underlying CFTR protein dysfunction, which leads to thickened secretions and obstruction of the pancreatic ducts. This causes progressive destruction of the exocrine pancreas, followed by fibrosis and fatty infiltration of the islets of Langerhans. Over time, beta-cell mass is reduced, impairing insulin secretion. However, the decline in insulin production is gradual. In early stages, the remaining beta cells can often compensate adequately during periods of stable health. The problem emerges during times of physiologic stress, such as acute pulmonary exacerbations, systemic glucocorticoid use, or high-calorie enteral feeds. These stressors unmask a relative insulin deficiency, leading to intermittent postprandial hyperglycemia. If left unchecked, chronic hyperglycemia itself further impairs beta-cell function in a glucotoxic loop, accelerates catabolism, and promotes a pro-inflammatory state that worsens CF lung disease. This pathophysiology explains why screening methods that rely on fasting glucose alone are ineffective in CFRD and why provocative testing is essential.

Screening Modalities: Strengths and Limitations

The Gold Standard: 2-Hour Oral Glucose Tolerance Test

Annual screening with the 2-hour oral glucose tolerance test (OGTT) beginning at age 10 remains the standard of care recommended by the Cystic Fibrosis Foundation, the American Diabetes Association, and the European Cystic Fibrosis Society. The test is performed after an overnight fast of at least eight hours. A glucose load of 1.75 grams per kilogram of body weight (maximum 75 grams) is administered orally, and plasma glucose is measured at fasting, 60 minutes, and 120 minutes. Interpretation follows established thresholds:

  • Normal glucose tolerance: Fasting glucose below 126 mg/dL and 2-hour glucose below 140 mg/dL.
  • Impaired glucose tolerance: 2-hour glucose between 140 and 199 mg/dL.
  • CFRD: Fasting glucose of 126 mg/dL or higher, or 2-hour glucose of 200 mg/dL or higher, confirmed on a separate day or accompanied by classic symptoms.
  • Indeterminate glycemia: 1-hour glucose of 200 mg/dL or higher with a normal 2-hour value, an emerging risk category linked to future progression to CFRD.

The OGTT is uniquely suited to CF because it effectively captures postprandial hyperglycemia, which is nearly always the earliest abnormality. Proper test conditions are critical: patients must be in their usual state of health, free from acute illness or pulmonary exacerbation, and should remain seated without strenuous activity during the test. Illness-related false positives can lead to unnecessary diagnostic confusion or inappropriate treatment.

The Limited Role of HbA1c and Fasting Glucose

Both hemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) perform poorly as screening tests in the CF population. HbA1c is falsely lowered in CF due to increased red blood cell turnover from chronic inflammation, hemolysis, and iron deficiency. Even when adjusted thresholds are used, HbA1c sensitivity for detecting CFRD ranges from only 40 to 60 percent. Similarly, fasting glucose is an inadequate screening tool because the majority of individuals with CFRD maintain normal fasting glucose until late in the disease process. Relying solely on these tests will delay diagnosis and miss the window for early intervention. Once CFRD is diagnosed, however, HbA1c may serve as a secondary metric for tracking long-term glycemic control, provided clinicians account for confounders like recent transfusion or iron status.

The Expanding Role of Continuous Glucose Monitoring

Continuous glucose monitoring (CGM) is rapidly gaining traction as a complementary screening and surveillance tool in CF care. CGM devices capture interstitial glucose levels every five to fifteen minutes, providing a detailed profile of glycemic variability over several days. Growing evidence demonstrates that CGM can detect abnormal glucose excursions—particularly postprandial spikes and nocturnal hyperglycemia—that are missed by a single annual OGTT. In many CF centers, CGM is now used to identify patients with early glucose abnormalities who might benefit from closer monitoring or preemptive nutritional and lifestyle counseling. Metrics such as time in range (TIR, often defined as glucose 70 to 180 mg/dL), time above range (TAR), and glycemic variability indices are being evaluated as potential diagnostic thresholds for CFRD. While CGM is not yet considered a standalone diagnostic tool for initial CFRD diagnosis, it offers practical advantages for ongoing monitoring, patient engagement, and guiding insulin therapy adjustments, particularly in patients with complex schedules or those unable to tolerate repeated OGTTs.

Implementing a Successful Screening Protocol

Frequency and Timing

Annual screening with OGTT is the minimum standard for all patients aged 10 years and older. However, certain clinical scenarios warrant more frequent testing. Patients with known impaired glucose tolerance should be retested at six-month intervals. Any episode requiring intravenous antibiotics or systemic corticosteroids for a pulmonary exacerbation should prompt repeat glucose evaluation after recovery. A rapid decline in lung function or unexplained weight loss, despite adequate caloric intake, should also trigger an immediate investigation for undiagnosed CFRD. There is currently no evidence to support extending the screening interval beyond one year, even in patients with a history of consistently normal OGTT results, because the risk of developing CFRD persists and increases with age.

Screening in Children Under 10 Years

Routine screening is not recommended before age 10 due to the low prevalence of CFRD in younger children. However, in children presenting with poor growth velocity, failure to thrive, recurrent pulmonary exacerbations, or unexplained decline in FEV1, an OGTT should be strongly considered regardless of age. Children receiving high-dose glucocorticoids for allergic bronchopulmonary aspergillosis or other indications are also at risk for transient or persistent hyperglycemia and merit glucose monitoring.

Pregnancy and CFRD

Pregnancy places significant metabolic stress on women with CF and can unmask underlying insulin deficiency. All pregnant women with CF should undergo a 75-gram OGTT at 24 to 28 weeks of gestation to screen for both gestational diabetes and CFRD. Women with known preexisting CFRD should receive preconception counseling to optimize glycemic control, as maternal hyperglycemia increases the risk of preterm delivery, low birth weight, and maternal infections. Close collaboration between CF specialists and maternal-fetal medicine teams is essential for managing these high-risk pregnancies.

Post-Transplant Monitoring

Individuals with CF who undergo solid organ transplantation, particularly lung or liver transplantation, are at elevated risk for new-onset diabetes after transplantation (NODAT). Immunosuppressive regimens containing calcineurin inhibitors and corticosteroids contribute to this risk. Screening should begin immediately after transplant and continue indefinitely. In this population, OGTT is more sensitive than fasting glucose or HbA1c. Aggressive glucose management is critical to reduce the risk of allograft rejection, serious infections, and cardiovascular complications.

Overcoming Barriers to Effective Screening

Despite clear guidelines, several barriers can impede consistent CFRD screening. The OGTT is time-intensive, requiring a dedicated two- to three-hour clinic visit, and many patients find the glucose solution unpalatable or nauseating. Adolescent and adult patients already manage complex daily CF treatment regimens, and adding an annual test perceived as burdensome can lead to reduced adherence. Psychological barriers, including fear of a diabetes diagnosis or diabetes distress, may also cause patients to avoid screening. CF care teams can address these barriers by clearly communicating the rationale for screening, emphasizing that early detection of CFRD leads to better overall health and fewer crises rather than adding complexity to care. Providing standardized written instructions for test preparation, allowing patients to remain in a comfortable setting during the test, and offering alternative screening methods such as CGM for ongoing surveillance where appropriate can improve acceptability. Involving CF dietitians, psychologists, and social workers in the education process reinforces the message that screening is an empowering tool rather than a punitive obligation.

The Impact of CFTR Modulators on CFRD Screening

The introduction of highly effective CFTR modulator therapies, particularly the combination of elexacaftor, tezacaftor, and ivacaftor (ETI), has revolutionized CF care by improving CFTR function and reducing disease progression in many patients. The effect of modulators on glucose tolerance is complex and varies among individuals. Some patients experience significant improvement in insulin secretion and normalization of glucose tolerance, likely due to reduced systemic inflammation and improved pancreatic function. Others may experience a decline in glycemic control, possibly related to rapid weight gain, improved nutritional absorption, and increased metabolic demand. Modulators do not eliminate the need for ongoing CFRD screening. In fact, as patients live longer and healthier lives, the cumulative lifetime risk of developing CFRD may remain substantial. Annual OGTT or CGM monitoring should continue for all patients on modulator therapy to detect changes in glucose status and guide timely intervention.

Clinical Outcomes and Benefits of Early Detection

Early detection of CFRD enables prompt initiation of insulin therapy, which remains the cornerstone of treatment. Unlike type 2 diabetes, CFRD is primarily an insulin-deficient state, and oral hypoglycemic agents are generally not recommended as first-line therapy. Insulin therapy in CFRD is associated with meaningful improvements in body mass index, stabilization of pulmonary function, and a reduction in the frequency of pulmonary exacerbations. Studies demonstrate that the decline in FEV1 can be slowed significantly when insulin therapy is started shortly after diagnosis. In contrast, a delay of even one year in diagnosis can result in a decline in lung function that is never fully recovered. Beyond pulmonary and nutritional benefits, effective glycemic control improves energy levels, reduces hospitalizations, and enhances quality of life. These outcomes highlight why adherence to screening guidelines is a key quality metric for CF care centers and a critical factor in improving long-term survival.

Future Directions in CFRD Detection and Management

Research continues to refine how CFRD is diagnosed and monitored. CGM-derived metrics, including time in range and glycemic variability, are being investigated as potential replacements for the OGTT in defining diagnostic thresholds. A consensus on CGM-based diagnostic criteria could simplify screening, reduce patient burden, and provide richer clinical data. Biomarkers beyond glucose, such as advanced glycation end-products, genetic risk scores, and measures of beta-cell function, may eventually identify patients who require earlier or more intensive screening. Automated insulin delivery systems, or artificial pancreas technology, initially developed for type 1 diabetes, are being explored for CFRD and may offer an integrated solution for those with severe insulin deficiency. As the CF population ages and modulators extend survival, the prevalence of CFRD and the importance of effective screening will only grow. Large, multicenter registries and pragmatic clinical trials will be essential to validate these emerging approaches and ensure that screening strategies remain aligned with the evolving needs of the CF community.

Summary and Key Recommendations

Cystic fibrosis–related diabetes is a distinct, progressive, and clinically consequential comorbidity that demands a proactive and systematic approach to detection. Annual 2-hour oral glucose tolerance testing beginning at age 10 is the established standard for screening, supported by robust evidence linking early diagnosis to improved clinical outcomes. Clinicians must recognize the limitations of fasting glucose and HbA1c and avoid using them as substitutes for the OGTT. Continuous glucose monitoring offers a valuable adjunct for risk stratification and ongoing management, particularly in patients with complex clinical courses or those on modulator therapy. Special populations, including children under 10 with growth failure, pregnant women, and post-transplant recipients, require tailored screening protocols. By embedding annual screening into routine CF care, educating patients and families about its importance, and treating identified CFRD promptly with insulin therapy, providers can help preserve lung function, support nutritional health, and reduce mortality in the CF population.

For detailed clinical guidance, refer to the Cystic Fibrosis Foundation clinical care guidelines on CFRD (CFF CFRD Guidelines) and the American Diabetes Association Standards of Care (ADA Standards of Care). Additional information on CGM use in CF can be found in the published literature on continuous glucose monitoring in cystic fibrosis.